{"id":"https://openalex.org/W1987145757","doi":"https://doi.org/10.1007/s00280-002-0508-5","title":"Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190","display_name":"Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190","publication_year":2002,"publication_date":"2002-11-01","ids":{"openalex":"https://openalex.org/W1987145757","doi":"https://doi.org/10.1007/s00280-002-0508-5","mag":"1987145757","pmid":"https://pubmed.ncbi.nlm.nih.gov/12439594"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-002-0508-5","doi":"https://doi.org/10.1007/s00280-002-0508-5","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-002-0508-5","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020105653","display_name":"Kazunori Samata","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]},{"id":"https://openalex.org/I159385669","display_name":"Chiba University","ror":"https://ror.org/01hjzeq58","country_code":"JP","type":"education","lineage":["https://openalex.org/I159385669"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Kazunori Samata","raw_affiliation_strings":["Graduate School of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi-cho, Inage-ku, Japan. kazunori.samata@po.rd.taisho.co.jp","Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Graduate School of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi-cho, Inage-ku, Japan. kazunori.samata@po.rd.taisho.co.jp","institution_ids":["https://openalex.org/I159385669"]},{"raw_affiliation_string":"Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Takehiro Yamagishi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takehiro Yamagishi","raw_affiliation_strings":["Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113720163","display_name":"Tomoko Ichihara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomoko Ichihara","raw_affiliation_strings":["Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083586293","display_name":"Kayoko Nanaumi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kayoko Nanaumi","raw_affiliation_strings":["Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074085996","display_name":"Tomotake Ikeda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomotake Ikeda","raw_affiliation_strings":["Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061780127","display_name":"Hisao Ikeya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hisao Ikeya","raw_affiliation_strings":["Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064450561","display_name":"Aiko Kuraishi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Aiko Kuraishi","raw_affiliation_strings":["Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002265537","display_name":"Shiro Nakaike","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144245601","display_name":"Taisho Pharmaceutical (Japan)","ror":"https://ror.org/033nw2736","country_code":"JP","type":"company","lineage":["https://openalex.org/I144245601"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shiro Nakaike","raw_affiliation_strings":["Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., 1-403 Yoshino-cho, Saitama 330-8530, Japan,","institution_ids":["https://openalex.org/I144245601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114251789","display_name":"Keiko Kashiwagi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I159385669","display_name":"Chiba University","ror":"https://ror.org/01hjzeq58","country_code":"JP","type":"education","lineage":["https://openalex.org/I159385669"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Keiko Kashiwagi","raw_affiliation_strings":["Graduate School of Pharmaceutical Sciences, Chiba University, 1-33, Yayoi-cho, Inage-ku, Chiba, 263-8522, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Graduate School of Pharmaceutical Sciences, Chiba University, 1-33, Yayoi-cho, Inage-ku, Chiba, 263-8522, Japan","institution_ids":["https://openalex.org/I159385669"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049477700","display_name":"Kazuei Igarashi","orcid":"https://orcid.org/0000-0003-3751-3187","observed_orcids":["https://orcid.org/0000-0003-3751-3187"]},"institutions":[{"id":"https://openalex.org/I159385669","display_name":"Chiba University","ror":"https://ror.org/01hjzeq58","country_code":"JP","type":"education","lineage":["https://openalex.org/I159385669"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kazuei Igarashi","raw_affiliation_strings":["Graduate School of Pharmaceutical Sciences, Chiba University, 1-33, Yayoi-cho, Inage-ku, Chiba, 263-8522, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Graduate School of Pharmaceutical Sciences, Chiba University, 1-33, Yayoi-cho, Inage-ku, Chiba, 263-8522, Japan","institution_ids":["https://openalex.org/I159385669"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5020105653"],"corresponding_institution_ids":["https://openalex.org/I144245601","https://openalex.org/I159385669"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":null,"fwci":0.0957,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.35049306,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":"50","issue":"5","first_page":"367","last_page":"372"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/topoisomerase-ii-inhibitors","display_name":"topoisomerase II inhibitors","score":0.8849999904632568},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.8980000019073486},{"id":"https://openalex.org/keywords/fm3a-cells","display_name":"FM3A cells","score":0.7390000224113464},{"id":"https://openalex.org/keywords/murine-mammary-carcinoma","display_name":"murine mammary carcinoma","score":0.9520000219345093},{"id":"https://openalex.org/keywords/topoisomerase-ii-alpha","display_name":"TOP2A","score":0.8410000205039978},{"id":"https://openalex.org/keywords/atp-binding-site","display_name":"ATP binding site","score":0.9240000247955322},{"id":"https://openalex.org/keywords/p-glycoprotein","display_name":"P-glycoprotein","score":0.8939999938011169},{"id":"https://openalex.org/keywords/cell-line-establishment","display_name":"cell line establishment","score":0.4309999942779541}],"concepts":[{"id":"https://openalex.org/C2778119113","wikidata":"https://www.wikidata.org/wiki/Q418817","display_name":"Etoposide","level":3,"score":0.9063407182693481},{"id":"https://openalex.org/C147897179","wikidata":"https://www.wikidata.org/wiki/Q407828","display_name":"Topoisomerase","level":3,"score":0.8779408931732178},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.7140426635742188},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.6372168660163879},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.605241596698761},{"id":"https://openalex.org/C2780500152","wikidata":"https://www.wikidata.org/wiki/Q2784004","display_name":"Amsacrine","level":4,"score":0.5962347984313965},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.46597573161125183},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.44407665729522705},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.23792317509651184},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09426233172416687},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.07966935634613037}],"mesh":[{"descriptor_ui":"D000255","descriptor_name":"Adenosine Triphosphate","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001665","descriptor_name":"Binding Sites","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D005047","descriptor_name":"Etoposide","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D008325","descriptor_name":"Mammary Neoplasms, Experimental","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009363","descriptor_name":"Neoplasm Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D010619","descriptor_name":"Phenazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D012333","descriptor_name":"RNA, Messenger","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D012334","descriptor_name":"RNA, Neoplasm","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D014407","descriptor_name":"Tumor Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018432","descriptor_name":"Drug Resistance, Multiple","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D019943","descriptor_name":"Amino Acid Substitution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D020125","descriptor_name":"Mutation, Missense","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059005","descriptor_name":"Topoisomerase II Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1007/s00280-002-0508-5","doi":"https://doi.org/10.1007/s00280-002-0508-5","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-002-0508-5","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmid:12439594","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12439594","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8048999905586243,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1428720349","https://openalex.org/W1476133568","https://openalex.org/W1523389730","https://openalex.org/W1531911812","https://openalex.org/W1775749144","https://openalex.org/W1818106540","https://openalex.org/W1954622523","https://openalex.org/W1973803579","https://openalex.org/W1985410947","https://openalex.org/W1991843596","https://openalex.org/W1992092714","https://openalex.org/W2003481405","https://openalex.org/W2016532443","https://openalex.org/W2018577228","https://openalex.org/W2027466925","https://openalex.org/W2030295874","https://openalex.org/W2047614940","https://openalex.org/W2064128298","https://openalex.org/W2069891078","https://openalex.org/W2088986997","https://openalex.org/W2100740357","https://openalex.org/W2100837269","https://openalex.org/W2101647884","https://openalex.org/W2102345056","https://openalex.org/W2317674943","https://openalex.org/W2444473145"],"related_works":["https://openalex.org/W2440161665","https://openalex.org/W1993247887","https://openalex.org/W1995644354","https://openalex.org/W1786775917","https://openalex.org/W2168336462","https://openalex.org/W1587797958","https://openalex.org/W1597583171","https://openalex.org/W2135376066","https://openalex.org/W2064263393","https://openalex.org/W1586201322"],"abstract_inverted_index":null,"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}